Laidlaw & Co. Downgrades EyePoint to Hold

Laidlaw & Co. analyst Yale Jen has downgraded EyePoint Pharmaceuticals (NASDAQ: EYPT) from a 'Buy' rating to 'Hold'. This change reflects a shift in the analyst's outlook on the company's stock performance.